GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

CKD-519 100mg

Company
Chong Kun Dang Pharmaceutical
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT02156544

    Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

    Not yet reported Chong Kun Dang Pharmaceutical 41 participants Est. completion 2015-08 1 site Stand-alone
    Other conditions: Dyslipidemia
    View official trial listing →
  • Completed NCT NCT02484482

    Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI)

    Not yet reported Chong Kun Dang Pharmaceutical 45 participants Est. completion 2015-08 1 site Stand-alone
    Other conditions: Dyslipidemia
    View official trial listing →
  • Completed NCT NCT02623868

    Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.

    Not yet reported Chong Kun Dang Pharmaceutical 30 participants Est. completion 2015-12 1 site Stand-alone
    Other conditions: Dyslipidemia
    View official trial listing →
  • Completed NCT NCT02753504

    Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

    Not yet reported Chong Kun Dang Pharmaceutical 24 participants Est. completion 2016-07 1 site Stand-alone
    Other conditions: Dyslipidemia
    View official trial listing →
  • Completed NCT NCT02894541

    Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519

    Not yet reported Chong Kun Dang Pharmaceutical 48 participants Est. completion 2017-01 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02916901

    Study to Investigate the Influence of CKD-519 on 24-h Ambulatory Blood Pressure in Healthy Adult Volunteers

    Not yet reported Chong Kun Dang Pharmaceutical 32 participants Est. completion 2017-01 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT03210649

    Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

    Not yet reported Chong Kun Dang Pharmaceutical 18 participants Est. completion 2017-04-24 1 site
    Other conditions: Dyslipidemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: CKD-519 100mg, CKD-519 200mg

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.